Parallel Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.97K | Buy |
157
+115
| +274% | +$2.53K | ﹤0.01% | 3307 |
|
|
2026
Q1 | $935 | Hold |
42
| – | – | ﹤0.01% | 3555 |
|
|
2025
Q4 | $1.12K | Sell |
42
-16
| -28% | -$382 | ﹤0.01% | 3268 |
|
|
2025
Q3 | $1.24K | Buy |
58
+16
| +38% | +$378 | ﹤0.01% | 3165 |
|
|
2025
Q2 | $906 | Sell |
42
-65
| -61% | -$1.21K | ﹤0.01% | 3214 |
|
|
2025
Q1 | $1.78K | Sell |
107
-34
| -24% | -$618 | ﹤0.01% | 3007 |
|
|
2024
Q4 | $2.59K | Buy |
141
+83
| +143% | +$1.34K | ﹤0.01% | 2880 |
|
|
2024
Q3 | $892 | Buy |
+58
| New | +$968 | ﹤0.01% | 3064 |
|
|
2024
Q2 | – | Sell |
-194
| Closed | -$3.59K | – | 3316 |
|
|
2024
Q1 | $3.59K | Hold |
194
| – | – | ﹤0.01% | 2626 |
|
|
2023
Q4 | $6.07K | Sell |
194
-130
| -40% | -$3.1K | ﹤0.01% | 2467 |
|
|
2023
Q3 | $6.75K | Buy |
324
+162
| +100% | +$4.4K | ﹤0.01% | 2374 |
|
|
2023
Q2 | $3.88K | Hold |
162
| – | – | ﹤0.01% | 2528 |
|
|
2023
Q1 | $3.05K | Hold |
162
| – | – | ﹤0.01% | 2604 |
|
|
2022
Q4 | $2.58K | Sell |
162
-92
| -36% | -$1.44K | ﹤0.01% | 2589 |
|
|
2022
Q3 | $4K | Buy |
254
+81
| +47% | +$1.31K | ﹤0.01% | 2356 |
|
|
2022
Q2 | $2K | Sell |
173
-321
| -65% | -$5.99K | ﹤0.01% | 2522 |
|
|
2022
Q1 | $12K | Sell |
494
-871
| -64% | -$21.1K | ﹤0.01% | 1918 |
|
|
2021
Q4 | $32K | Buy |
1,365
+584
| +75% | +$11.7K | ﹤0.01% | 1561 |
|
|
2021
Q3 | $13K | Buy |
781
+461
| +144% | +$8.89K | ﹤0.01% | 1930 |
|
|
2021
Q2 | $8K | Buy |
320
+44
| +16% | +$993 | ﹤0.01% | 2084 |
|
|
2021
Q1 | $7K | Buy |
276
+95
| +52% | +$4.18K | ﹤0.01% | 2044 |
|
|
2020
Q4 | $10K | Buy |
181
+3
| +2% | +$149 | ﹤0.01% | 1768 |
|
|
2020
Q3 | $7K | Buy |
178
+16
| +10% | +$691 | ﹤0.01% | 1871 |
|
|
2020
Q2 | $7K | Hold |
162
| – | – | ﹤0.01% | 1825 |
|
|
2020
Q1 | $6K | Hold |
162
| – | – | ﹤0.01% | 1808 |
|
|
2019
Q4 | $7K | Hold |
162
| – | – | ﹤0.01% | 1837 |
|
|
2019
Q3 | $6K | Hold |
162
| – | – | ﹤0.01% | 1842 |
|
|
2019
Q2 | $4K | Hold |
162
| – | – | ﹤0.01% | 1872 |
|
|
2019
Q1 | $4K | Hold |
162
| – | – | ﹤0.01% | 1829 |
|
|
2018
Q4 | $2K | Hold |
162
| – | – | ﹤0.01% | 1830 |
|
|
2018
Q3 | $3K | Buy |
162
+129
| +391% | +$2.03K | ﹤0.01% | 1864 |
|
|
2018
Q2 | $0 | Sell |
33
-170
| -84% | -$3.03K | ﹤0.01% | 2074 |
|
|
2018
Q1 | $5K | Buy |
203
+33
| +19% | +$914 | ﹤0.01% | 1526 |
|
|
2017
Q4 | $5K | Hold |
170
| – | – | ﹤0.01% | 1540 |
|
|
2017
Q3 | $5K | Hold |
170
| – | – | ﹤0.01% | 1551 |
|
|
2017
Q2 | $5K | Sell |
170
-25
| -13% | -$745 | ﹤0.01% | 1573 |
|
|
2017
Q1 | $6K | Buy |
195
+25
| +15% | +$882 | ﹤0.01% | 1386 |
|
|
2016
Q4 | $5K | Buy |
+170
| New | +$4.5K | ﹤0.01% | 1342 |
|
Other funds holding ACAD
PAM
RHJA
Parallel Advisors's ACAD Position: Q2 2026 in Review
Parallel Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 274% in Q2 2026, buying an estimated $2.53K and bringing the position to 157 shares worth $3.97K. The position accounts for ﹤0.01% of the portfolio, ranked #3307.
Parallel Advisors first reported a position in ACAD in Q4 2016 and has held it in 38 quarters since. The position peaked at $32K in Q4 2021. 138 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Parallel Advisors held 157 shares of Acadia Pharmaceuticals worth $3.97K as of Q2 2026.
- Parallel Advisors bought 115 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.53K.
- Acadia Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3307 holding.
- Parallel Advisors first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Acadia Pharmaceuticals position peaked at $32K in Q4 2021.
- 138 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.